speb/financial-data huggingface dataset:
DRM.TO cash_flow (quarterly, 2025-12-31) — Sale Of Investment Properties: 8121000.00
DRM.TO income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 8640000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: -20750000.00
DRM.TO income_statement (annual, 2025-12-31) — Selling General And Administration: 62629000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Selling General And Administration: 15272000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Share Issued: 41985939.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Share Issued: 41985939.00
DRM.TO cash_flow (annual, 2025-12-31) — Short Term Debt Issuance: 18500000.00
DRM.TO income_statement (annual, 2025-12-31) — Special Income Charges: 45339000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Special Income Charges: 16341000.00
DRM.TO cash_flow (annual, 2025-12-31) — Stock Based Compensation: 2908000.00
DRM.TO cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 2259000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Stockholders Equity: 1457148000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 1457148000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Tangible Book Value: 1445120000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 1445120000.00
DRM.TO income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 2395650.00
DRM.TO income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 2451357.59
DRM.TO income_statement (annual, 2025-12-31) — Tax Provision: 9946000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Tax Provision: 18593000.00
DRM.TO income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.15
DRM.TO income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.39
DRM.TO balance_sheet (annual, 2025-12-31) — Taxes Receivable: 4025000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 4025000.00
DRM.TO cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -36567000.00
DRM.TO cash_flow (quarterly, 2025-12-31) — Taxes Refund Paid: -2128000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Assets: 3993122000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Assets: 3993122000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Capitalization: 3376331000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 3376331000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Debt: 1923163000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Debt: 1923163000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 1457148000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 1457148000.00
DRM.TO income_statement (annual, 2025-12-31) — Total Expenses: 339478000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Total Expenses: 117663000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 2535974000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 2535974000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 2543818000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 2543818000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 2130870000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 2130870000.00
DRM.TO income_statement (annual, 2025-12-31) — Total Other Finance Cost: 2405000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Total Other Finance Cost: 402000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Total Tax Payable: 0.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 0.00
DRM.TO income_statement (annual, 2025-12-31) — Total Unusual Items: 15971000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Total Unusual Items: 6293000.00
DRM.TO income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: 15971000.00
DRM.TO income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 6293000.00
DRM.TO cash_flow (annual, 2025-12-31) — Unrealized Gain Loss On Investment Securities: -2793000.00
DRM.TO cash_flow (quarterly, 2025-12-31) — Unrealized Gain Loss On Investment Securities: -4442000.00
DRM.TO balance_sheet (annual, 2025-12-31) — Working Capital: 1044200000.00
DRM.TO balance_sheet (quarterly, 2025-12-31) — Working Capital: 1044200000.00
DRM.TO income_statement (quarterly, 2026-03-31) — +Operating Expense: 15816000.00
DRM.TO income_statement (quarterly, 2026-03-31) — +Total Revenue: 67428000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 71613000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 235727000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -16585000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 10356000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 0.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 23065000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Basic Average Shares: 41949125.00
DRM.TO income_statement (quarterly, 2026-03-31) — Basic EPS: -0.11
DRM.TO cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 57692000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 1253000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Capital Stock: 955521000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 72761000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 72761000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -7361000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 26091000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -43044000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 32022000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 9457000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: 4608000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Change In Payable: 9457000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 9457000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 1704000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Change In Receivables: 40994000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 56763000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 40994000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Changes In Cash: 15069000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Common Stock: 955521000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Common Stock Dividend Paid: -7361000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 1441946000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -5281000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 46104000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 166315000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Assets: 1224233000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Debt: 1775000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1775000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 54217000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 54217000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 370954000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Current Provisions: 77034000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -7739000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Deferred Tax: -7739000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Depreciation: 1240000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 1240000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 1240000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 1453000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 41949125.00
DRM.TO income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.11
DRM.TO income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -4808000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Dividends Received Cfi: 15762000.00
DRM.TO income_statement (quarterly, 2026-03-31) — EBIT: 11976000.00
DRM.TO income_statement (quarterly, 2026-03-31) — EBITDA: 13216000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest: -1524000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: 1524000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — End Cash Position: 72761000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Financial Assets: 1426000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 26091000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Finished Goods: 867463000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 32022000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: -5400000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: 5400000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 14848000.00
DRM.TO income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 6804000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Goodwill: 12028000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 12028000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Gross PPE: 24408000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Gross Profit: 21324000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Interest Expense: 16902000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 16902000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Inventory: 867463000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Invested Capital: 3442591000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -43044000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Investment Properties: 2122752000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 23065000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 602635000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 97354000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Line Of Credit: 1775000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Loans Receivable: 32678000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 1253000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 1998870000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 2000123000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 97354000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -58621000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 579570000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -4269000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -5281000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Net Debt: 1927884000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Income: -4808000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -4808000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -4808000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -4808000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -4808000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -4808000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -4808000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Interest Income: -16902000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Investment Properties Purchase And Sale: -55176000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 666000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 38733000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 38733000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -16902000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: -27000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Net PPE: 7823000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 1429918000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Non Current Accounts Receivable: 36385000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 62652000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 62652000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 7244000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Normalized Income: -10636943.56
DRM.TO cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 32022000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -3876000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Operating Income: 5508000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Operating Revenue: 43661000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 42072897.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 14848000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: -944577000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Other Gand A: 6804000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Other Income Expense: 6468000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 2226000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 6683000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 136837000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 2020000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Other Properties: 24408000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Payables: 71613000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 237928000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 7434000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Pretax Income: -4926000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -4269000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: 0.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Purchase Of Investment Properties: -70103000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Receivables: 271926000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 46104000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 1240000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -58621000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -5281000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 4649000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: -572000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 1405798000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 666000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Sale Of Investment Properties: 14927000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 9012000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Selling General And Administration: 15816000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Share Issued: 42072897.00
DRM.TO income_statement (quarterly, 2026-03-31) — Special Income Charges: 572000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: -3622000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 1441946000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 1429918000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 143056.44
DRM.TO income_statement (quarterly, 2026-03-31) — Tax Provision: -118000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.02
DRM.TO balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 3521000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Taxes Refund Paid: -7022000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Total Assets: 4013965000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 3440816000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Total Debt: 2001898000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 1441946000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Total Expenses: 61920000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 2572019000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 2789732000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2201065000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Total Unusual Items: 5972000.00
DRM.TO income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 5972000.00
DRM.TO cash_flow (quarterly, 2026-03-31) — Unrealized Gain Loss On Investment Securities: -1140000.00
DRM.TO balance_sheet (quarterly, 2026-03-31) — Working Capital: 853279000.00
DRMA balance_sheet (annual, 2021-12-31) — Cash Financial: 10798806.00
DRMA cash_flow (annual, 2021-12-31) — Change In Other Current Liabilities: 0.00
DRMA balance_sheet (annual, 2021-12-31) — Current Deferred Assets: 55718.00
DRMA cash_flow (annual, 2021-12-31) — Depreciation: 0.00
DRMA cash_flow (annual, 2021-12-31) — Depreciation Amortization Depletion: 0.00
DRMA cash_flow (annual, 2021-12-31) — Depreciation And Amortization: 0.00
DRMA income_statement (annual, 2021-12-31) — General And Administrative Expense: 4397524.00
DRMA income_statement (annual, 2021-12-31) — Interest Expense: 45613.00
DRMA income_statement (annual, 2021-12-31) — Interest Expense Non Operating: 45613.00
DRMA cash_flow (annual, 2021-12-31) — Interest Paid Supplemental Data: 1420.00
DRMA balance_sheet (annual, 2021-12-31) — Interest Payable: 0.00
DRMA cash_flow (annual, 2021-12-31) — Issuance Of Debt: 1562717.00
DRMA cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 1562717.00
DRMA cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -556482.00
DRMA cash_flow (annual, 2021-12-31) — Net Issuance Payments Of Debt: 1006235.00
DRMA cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: 1006235.00
DRMA cash_flow (annual, 2021-12-31) — Net Preferred Stock Issuance: -430000.00
DRMA cash_flow (annual, 2021-12-31) — Net Short Term Debt Issuance: 1006235.00
DRMA income_statement (annual, 2021-12-31) — Other Gand A: 4397524.00
DRMA cash_flow (annual, 2021-12-31) — Other Non Cash Items: 14126.00
DRMA income_statement (annual, 2021-12-31) — Preferred Stock Dividends: 2562237.00
DRMA cash_flow (annual, 2021-12-31) — Preferred Stock Issuance: 570000.00
DRMA cash_flow (annual, 2021-12-31) — Preferred Stock Payments: -1000000.00
DRMA income_statement (annual, 2021-12-31) — Reconciled Depreciation: 0.00
DRMA cash_flow (annual, 2021-12-31) — Repayment Of Debt: -556482.00
DRMA cash_flow (annual, 2021-12-31) — Short Term Debt Issuance: 1562717.00
DRMA cash_flow (annual, 2021-12-31) — Short Term Debt Payments: -556482.00
DRMA income_statement (annual, 2021-12-31) — Special Income Charges: 0.00
DRMA income_statement (annual, 2021-12-31) — Total Other Finance Cost: 45613.00
DRMA income_statement (annual, 2021-12-31) — Total Unusual Items: 0.00
DRMA income_statement (annual, 2021-12-31) — Total Unusual Items Excluding Goodwill: 0.00
DRMA income_statement (annual, 2022-12-31) — +Operating Expense: 9674486.00
DRMA income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Accounts Payable: 496702.00
DRMA balance_sheet (annual, 2022-12-31) — Accrued Interest Receivable: 12602.00
DRMA balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 51614965.00
DRMA income_statement (annual, 2022-12-31) — Basic Average Shares: 4604.00
DRMA income_statement (annual, 2022-12-31) — Basic EPS: -2088.00
DRMA cash_flow (annual, 2022-12-31) — Beginning Cash Position: 10798806.00
DRMA balance_sheet (annual, 2022-12-31) — Capital Stock: 77.00
DRMA balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 6241294.00
DRMA balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 6241294.00
DRMA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 4276652.00
DRMA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -8834164.00
DRMA cash_flow (annual, 2022-12-31) — Change In Account Payable: -18543.00
DRMA cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -256973.00
DRMA cash_flow (annual, 2022-12-31) — Change In Payable: -18543.00
DRMA cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -275516.00
DRMA cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 121940.00
DRMA cash_flow (annual, 2022-12-31) — Change In Working Capital: -153576.00
DRMA cash_flow (annual, 2022-12-31) — Changes In Cash: -4557512.00
DRMA balance_sheet (annual, 2022-12-31) — Common Stock: 77.00
DRMA balance_sheet (annual, 2022-12-31) — Common Stock Equity: 6021854.00
DRMA cash_flow (annual, 2022-12-31) — Common Stock Issuance: 4276365.00
DRMA cash_flow (annual, 2022-12-31) — Common Stock Payments: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 255543.00
DRMA balance_sheet (annual, 2022-12-31) — Current Assets: 6944488.00
DRMA balance_sheet (annual, 2022-12-31) — Current Deferred Assets: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Current Liabilities: 922634.00
DRMA income_statement (annual, 2022-12-31) — Diluted Average Shares: 4604.00
DRMA income_statement (annual, 2022-12-31) — Diluted EPS: -2088.00
DRMA income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -9610913.00
DRMA income_statement (annual, 2022-12-31) — EBIT: -9674486.00
DRMA income_statement (annual, 2022-12-31) — EBITDA: -9674486.00
DRMA cash_flow (annual, 2022-12-31) — End Cash Position: 6241294.00
DRMA cash_flow (annual, 2022-12-31) — Financing Cash Flow: 4276652.00
DRMA cash_flow (annual, 2022-12-31) — Free Cash Flow: -8834164.00
DRMA income_statement (annual, 2022-12-31) — General And Administrative Expense: 4023445.00
DRMA cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 950.00
DRMA income_statement (annual, 2022-12-31) — Interest Expense: -63573.00
DRMA income_statement (annual, 2022-12-31) — Interest Expense Non Operating: -63573.00
DRMA income_statement (annual, 2022-12-31) — Interest Income: 63573.00
DRMA income_statement (annual, 2022-12-31) — Interest Income Non Operating: 63573.00
DRMA cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Invested Capital: 6021854.00
DRMA cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 4276365.00
DRMA cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
DRMA cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
DRMA cash_flow (annual, 2022-12-31) — Long Term Debt Payments: 0.00
DRMA cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 4276365.00
DRMA income_statement (annual, 2022-12-31) — Net Income: -9610913.00
DRMA income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -9610913.00
DRMA income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -9610913.00
DRMA income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -9610913.00
DRMA income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -9610913.00
DRMA cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -9610913.00
DRMA income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -9610913.00
DRMA income_statement (annual, 2022-12-31) — Net Interest Income: 63573.00
DRMA cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 0.00
DRMA cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: 0.00
DRMA income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 63573.00
DRMA cash_flow (annual, 2022-12-31) — Net Preferred Stock Issuance: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 6021854.00
DRMA income_statement (annual, 2022-12-31) — Normalized EBITDA: -9674486.00
DRMA income_statement (annual, 2022-12-31) — Normalized Income: -9610913.00
DRMA cash_flow (annual, 2022-12-31) — Operating Cash Flow: -8834164.00
DRMA income_statement (annual, 2022-12-31) — Operating Income: -9674486.00
DRMA income_statement (annual, 2022-12-31) — Operating Revenue: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 5134.00
DRMA balance_sheet (annual, 2022-12-31) — Other Current Assets: 11604.00
DRMA income_statement (annual, 2022-12-31) — Other Gand A: 4023445.00
DRMA balance_sheet (annual, 2022-12-31) — Other Receivables: 12602.00
DRMA balance_sheet (annual, 2022-12-31) — Payables: 496702.00
DRMA balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 752245.00
DRMA balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 170389.00
DRMA cash_flow (annual, 2022-12-31) — Preferred Stock Issuance: 0.00
DRMA cash_flow (annual, 2022-12-31) — Preferred Stock Payments: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Prepaid Assets: 690592.00
DRMA income_statement (annual, 2022-12-31) — Pretax Income: -9610913.00
DRMA cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 287.00
DRMA balance_sheet (annual, 2022-12-31) — Receivables: 12602.00
DRMA cash_flow (annual, 2022-12-31) — Repayment Of Debt: 0.00
DRMA cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: 0.00
DRMA income_statement (annual, 2022-12-31) — Research And Development: 5651041.00
DRMA balance_sheet (annual, 2022-12-31) — Retained Earnings: -45593188.00
DRMA income_statement (annual, 2022-12-31) — Selling General And Administration: 4023445.00
DRMA balance_sheet (annual, 2022-12-31) — Share Issued: 5134.00
DRMA cash_flow (annual, 2022-12-31) — Stock Based Compensation: 930325.00
DRMA balance_sheet (annual, 2022-12-31) — Stockholders Equity: 6021854.00
DRMA balance_sheet (annual, 2022-12-31) — Tangible Book Value: 6021854.00
DRMA income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Total Assets: 6944488.00
DRMA balance_sheet (annual, 2022-12-31) — Total Capitalization: 6021854.00
DRMA balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 6021854.00
DRMA income_statement (annual, 2022-12-31) — Total Expenses: 9674486.00
DRMA balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 922634.00
DRMA balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 0.00
DRMA balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -9674486.00
DRMA income_statement (annual, 2022-12-31) — Total Other Finance Cost: -63573.00
DRMA balance_sheet (annual, 2022-12-31) — Working Capital: 6021854.00
DRMA income_statement (annual, 2023-12-31) — +Operating Expense: 8041906.00
DRMA income_statement (annual, 2023-12-31) — +Total Revenue: 0.00
DRMA balance_sheet (annual, 2023-12-31) — Accounts Payable: 866028.00
DRMA balance_sheet (annual, 2023-12-31) — Accrued Interest Receivable: 8356.00
DRMA balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 59742870.00
DRMA income_statement (annual, 2023-12-31) — Basic Average Shares: 19492.00
DRMA income_statement (annual, 2023-12-31) — Basic EPS: -399.90
DRMA cash_flow (annual, 2023-12-31) — Beginning Cash Position: 6241294.00
DRMA balance_sheet (annual, 2023-12-31) — Capital Stock: 26.00
DRMA balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 7438135.00
DRMA balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 7438135.00
DRMA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 7605772.00
DRMA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -6408931.00
DRMA cash_flow (annual, 2023-12-31) — Change In Account Payable: 369326.00
DRMA cash_flow (annual, 2023-12-31) — Change In Accrued Expense: 331656.00
DRMA cash_flow (annual, 2023-12-31) — Change In Payable: 369326.00
DRMA cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 700982.00
DRMA cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 162695.00
DRMA cash_flow (annual, 2023-12-31) — Change In Working Capital: 863677.00
DRMA cash_flow (annual, 2023-12-31) — Changes In Cash: 1196841.00
DRMA balance_sheet (annual, 2023-12-31) — Common Stock: 26.00
DRMA balance_sheet (annual, 2023-12-31) — Common Stock Equity: 6355018.00
DRMA cash_flow (annual, 2023-12-31) — Common Stock Issuance: 7605625.00
DRMA cash_flow (annual, 2023-12-31) — Common Stock Payments: -40.00
DRMA balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 41098.00
DRMA balance_sheet (annual, 2023-12-31) — Current Assets: 7978634.00
DRMA balance_sheet (annual, 2023-12-31) — Current Liabilities: 1623616.00
DRMA income_statement (annual, 2023-12-31) — Diluted Average Shares: 19492.00
DRMA income_statement (annual, 2023-12-31) — Diluted EPS: -399.90
DRMA income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -7794690.00
DRMA income_statement (annual, 2023-12-31) — EBIT: -8041906.00
DRMA income_statement (annual, 2023-12-31) — EBITDA: -8041906.00
DRMA cash_flow (annual, 2023-12-31) — End Cash Position: 7438135.00
DRMA cash_flow (annual, 2023-12-31) — Financing Cash Flow: 7605772.00
DRMA cash_flow (annual, 2023-12-31) — Free Cash Flow: -6408931.00
DRMA income_statement (annual, 2023-12-31) — General And Administrative Expense: 3972140.00
DRMA cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 950.00
DRMA income_statement (annual, 2023-12-31) — Interest Income: 247216.00
DRMA income_statement (annual, 2023-12-31) — Interest Income Non Operating: 247216.00
DRMA balance_sheet (annual, 2023-12-31) — Invested Capital: 6355018.00
DRMA cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 7605625.00
DRMA cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 7605585.00
DRMA income_statement (annual, 2023-12-31) — Net Income: -7794690.00
DRMA income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -7794690.00
DRMA income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -7794690.00
DRMA income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -7794690.00
DRMA income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -7794690.00
DRMA cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -7794690.00
DRMA income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -7794690.00
DRMA income_statement (annual, 2023-12-31) — Net Interest Income: 247216.00
DRMA income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 247216.00
DRMA balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 6355018.00
DRMA income_statement (annual, 2023-12-31) — Normalized EBITDA: -8041906.00
DRMA income_statement (annual, 2023-12-31) — Normalized Income: -7794690.00
DRMA cash_flow (annual, 2023-12-31) — Operating Cash Flow: -6408931.00
DRMA income_statement (annual, 2023-12-31) — Operating Income: -8041906.00
DRMA income_statement (annual, 2023-12-31) — Operating Revenue: 0.00
DRMA balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 26205.00
DRMA balance_sheet (annual, 2023-12-31) — Other Current Assets: 14498.00
DRMA income_statement (annual, 2023-12-31) — Other Gand A: 3972140.00
DRMA balance_sheet (annual, 2023-12-31) — Payables: 866028.00
DRMA balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 907126.00
DRMA balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 716490.00
DRMA balance_sheet (annual, 2023-12-31) — Prepaid Assets: 540499.00
DRMA income_statement (annual, 2023-12-31) — Pretax Income: -7794690.00
DRMA cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 187.00
DRMA balance_sheet (annual, 2023-12-31) — Receivables: 8356.00
DRMA cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -40.00
DRMA income_statement (annual, 2023-12-31) — Research And Development: 4069766.00
DRMA balance_sheet (annual, 2023-12-31) — Retained Earnings: -53387878.00
DRMA income_statement (annual, 2023-12-31) — Selling General And Administration: 3972140.00
DRMA balance_sheet (annual, 2023-12-31) — Share Issued: 26205.00
DRMA cash_flow (annual, 2023-12-31) — Stock Based Compensation: 522082.00
DRMA balance_sheet (annual, 2023-12-31) — Stockholders Equity: 6355018.00
DRMA balance_sheet (annual, 2023-12-31) — Tangible Book Value: 6355018.00
DRMA income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (annual, 2023-12-31) — Total Assets: 7978634.00
DRMA balance_sheet (annual, 2023-12-31) — Total Capitalization: 6355018.00
DRMA balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 6355018.00
DRMA income_statement (annual, 2023-12-31) — Total Expenses: 8041906.00
DRMA balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 1623616.00
DRMA balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 0.00
DRMA balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -8041906.00
DRMA balance_sheet (annual, 2023-12-31) — Working Capital: 6355018.00
DRMA income_statement (quarterly, 2024-09-30) — Basic Average Shares: 155465.00
DRMA income_statement (quarterly, 2024-09-30) — Basic EPS: -20.41
DRMA cash_flow (quarterly, 2024-09-30) — Common Stock Payments: 0.00
DRMA income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 155465.00
DRMA income_statement (quarterly, 2024-09-30) — Diluted EPS: -20.41
DRMA cash_flow (quarterly, 2024-09-30) — Income Tax Paid Supplemental Data: 0.00
DRMA balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 37030.00
DRMA cash_flow (quarterly, 2024-09-30) — Repurchase Of Capital Stock: 0.00
DRMA income_statement (quarterly, 2024-09-30) — Salaries And Wages: 261517.00
DRMA income_statement (quarterly, 2024-09-30) — Selling And Marketing Expense: 0.00
DRMA income_statement (annual, 2024-12-31) — +Operating Expense: 12513242.00
DRMA income_statement (annual, 2024-12-31) — +Total Revenue: 0.00
DRMA balance_sheet (annual, 2024-12-31) — Accounts Payable: 808011.00
DRMA balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 67236408.00
DRMA income_statement (annual, 2024-12-31) — Basic Average Shares: 152974.00
DRMA income_statement (annual, 2024-12-31) — Basic EPS: -80.32
DRMA cash_flow (annual, 2024-12-31) — Beginning Cash Position: 7438135.00
DRMA balance_sheet (annual, 2024-12-31) — Capital Stock: 25.00
DRMA balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 3161570.00
DRMA balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 3161570.00
DRMA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 6886383.00
DRMA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -11162948.00
DRMA cash_flow (annual, 2024-12-31) — Change In Account Payable: -108512.00
DRMA cash_flow (annual, 2024-12-31) — Change In Accrued Expense: 407195.00
DRMA cash_flow (annual, 2024-12-31) — Change In Payable: -108512.00
DRMA cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 298683.00
DRMA cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 168181.00
DRMA cash_flow (annual, 2024-12-31) — Change In Working Capital: 466864.00
DRMA cash_flow (annual, 2024-12-31) — Changes In Cash: -4276565.00
DRMA balance_sheet (annual, 2024-12-31) — Common Stock: 25.00
DRMA balance_sheet (annual, 2024-12-31) — Common Stock Equity: 1561094.00
DRMA cash_flow (annual, 2024-12-31) — Common Stock Issuance: 6886102.00
DRMA cash_flow (annual, 2024-12-31) — Common Stock Payments: -828.00
DRMA cash_flow (quarterly, 2024-12-31) — Common Stock Payments: 0.00
DRMA balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 433151.00
DRMA balance_sheet (annual, 2024-12-31) — Current Assets: 3533888.00
DRMA balance_sheet (annual, 2024-12-31) — Current Liabilities: 1972794.00
DRMA income_statement (annual, 2024-12-31) — Diluted Average Shares: 152974.00
DRMA income_statement (annual, 2024-12-31) — Diluted EPS: -80.32
DRMA income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -12287461.00
DRMA income_statement (annual, 2024-12-31) — EBIT: -12513242.00
DRMA income_statement (annual, 2024-12-31) — EBITDA: -12513242.00
DRMA cash_flow (annual, 2024-12-31) — End Cash Position: 3161570.00
DRMA cash_flow (annual, 2024-12-31) — Financing Cash Flow: 6886383.00
DRMA cash_flow (annual, 2024-12-31) — Free Cash Flow: -11162948.00
DRMA income_statement (annual, 2024-12-31) — General And Administrative Expense: 4309551.00
DRMA income_statement (quarterly, 2024-12-31) — General And Administrative Expense: 1007798.00
DRMA cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 950.00
DRMA cash_flow (quarterly, 2024-12-31) — Income Tax Paid Supplemental Data: 0.00
DRMA income_statement (annual, 2024-12-31) — Interest Income: 225781.00
DRMA income_statement (annual, 2024-12-31) — Interest Income Non Operating: 225781.00
DRMA balance_sheet (annual, 2024-12-31) — Invested Capital: 1561094.00
DRMA cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 6886102.00
DRMA cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 6885274.00
DRMA income_statement (annual, 2024-12-31) — Net Income: -12287461.00
DRMA income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -12287461.00
DRMA income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -12287461.00
DRMA income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -12287461.00
DRMA income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -12287461.00
DRMA cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -12287461.00
DRMA income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -12287461.00
DRMA income_statement (annual, 2024-12-31) — Net Interest Income: 225781.00
DRMA income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 225781.00
DRMA balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 1561094.00
DRMA income_statement (annual, 2024-12-31) — Normalized EBITDA: -12513242.00
DRMA income_statement (annual, 2024-12-31) — Normalized Income: -12287461.00
DRMA cash_flow (annual, 2024-12-31) — Operating Cash Flow: -11162948.00
DRMA income_statement (annual, 2024-12-31) — Operating Income: -12513242.00
DRMA income_statement (annual, 2024-12-31) — Operating Revenue: 0.00
DRMA balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 251776.00
DRMA income_statement (annual, 2024-12-31) — Other Gand A: 4309551.00
DRMA income_statement (quarterly, 2024-12-31) — Other Gand A: 1007798.00
DRMA balance_sheet (annual, 2024-12-31) — Payables: 808011.00
DRMA balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 1241162.00
DRMA balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 731632.00
DRMA balance_sheet (annual, 2024-12-31) — Prepaid Assets: 372318.00
DRMA income_statement (annual, 2024-12-31) — Pretax Income: -12287461.00
DRMA cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 1109.00
DRMA cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -828.00
DRMA cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: 0.00
DRMA income_statement (annual, 2024-12-31) — Research And Development: 8203691.00
DRMA balance_sheet (annual, 2024-12-31) — Retained Earnings: -65675339.00
DRMA income_statement (annual, 2024-12-31) — Selling General And Administration: 4309551.00
DRMA balance_sheet (annual, 2024-12-31) — Share Issued: 251776.00
DRMA cash_flow (annual, 2024-12-31) — Stock Based Compensation: 657649.00
DRMA balance_sheet (annual, 2024-12-31) — Stockholders Equity: 1561094.00
DRMA balance_sheet (annual, 2024-12-31) — Tangible Book Value: 1561094.00
DRMA income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (annual, 2024-12-31) — Total Assets: 3533888.00
DRMA balance_sheet (annual, 2024-12-31) — Total Capitalization: 1561094.00
DRMA balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 1561094.00
DRMA income_statement (annual, 2024-12-31) — Total Expenses: 12513242.00
DRMA balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 1972794.00
DRMA balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 0.00
DRMA balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRMA income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -12513242.00
DRMA balance_sheet (annual, 2024-12-31) — Working Capital: 1561094.00
DRMA income_statement (quarterly, 2025-03-31) — +Operating Expense: 2339803.00
DRMA income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
DRMA balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 1395313.00
DRMA balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 75279545.00
DRMA income_statement (quarterly, 2025-03-31) — Basic Average Shares: 515465.00
DRMA income_statement (quarterly, 2025-03-31) — Basic EPS: -4.47
DRMA cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 3161570.00
DRMA balance_sheet (quarterly, 2025-03-31) — Capital Stock: 603.00
DRMA balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 9719268.00
DRMA balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 9719268.00
DRMA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 8491764.00
DRMA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -1934066.00
DRMA cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 102064.00
DRMA cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: 143689.00
DRMA cash_flow (quarterly, 2025-03-31) — Change In Inventory: 0.00
DRMA cash_flow (quarterly, 2025-03-31) — Change In Payable: 102064.00
DRMA cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 245753.00
DRMA cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 86579.00
DRMA cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 332332.00
DRMA cash_flow (quarterly, 2025-03-31) — Changes In Cash: 6557698.00
DRMA balance_sheet (quarterly, 2025-03-31) — Common Stock: 603.00
DRMA balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 7301222.00
DRMA cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 8541282.00
DRMA balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 346713.00
DRMA balance_sheet (quarterly, 2025-03-31) — Current Assets: 10005007.00
DRMA balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 2703785.00
DRMA income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 515465.00
DRMA income_statement (quarterly, 2025-03-31) — Diluted EPS: -4.47
DRMA income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -2303587.00
DRMA income_statement (quarterly, 2025-03-31) — EBIT: -2339803.00
DRMA income_statement (quarterly, 2025-03-31) — EBITDA: -2339803.00
DRMA cash_flow (quarterly, 2025-03-31) — End Cash Position: 9719268.00
DRMA cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 8491764.00
DRMA cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -1934066.00
DRMA income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 1058662.00
DRMA income_statement (quarterly, 2025-03-31) — Interest Income: 36216.00
DRMA income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 36216.00
DRMA balance_sheet (quarterly, 2025-03-31) — Invested Capital: 7301222.00
DRMA cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 8541282.00
DRMA cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 8541282.00
DRMA income_statement (quarterly, 2025-03-31) — Net Income: -2303587.00
DRMA income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -2303587.00
DRMA income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -2303587.00
DRMA income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -2303587.00
DRMA income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -2303587.00
DRMA cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -2303587.00
DRMA income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -2303587.00
DRMA income_statement (quarterly, 2025-03-31) — Net Interest Income: 36216.00
DRMA income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 36216.00
DRMA cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -50495.00
DRMA balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 7301222.00
DRMA income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -2339803.00
DRMA income_statement (quarterly, 2025-03-31) — Normalized Income: -2303587.00
DRMA cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -1934066.00
DRMA income_statement (quarterly, 2025-03-31) — Operating Income: -2339803.00
DRMA income_statement (quarterly, 2025-03-31) — Operating Revenue: 0.00
DRMA balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 603264.00
DRMA balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 75511.00
DRMA income_statement (quarterly, 2025-03-31) — Other Gand A: 719644.00
DRMA balance_sheet (quarterly, 2025-03-31) — Payables: 1395313.00
DRMA balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 1742026.00
DRMA balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 961759.00
DRMA balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 210228.00
DRMA income_statement (quarterly, 2025-03-31) — Pretax Income: -2303587.00
DRMA cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 977.00
DRMA income_statement (quarterly, 2025-03-31) — Research And Development: 1281141.00
DRMA balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -67978926.00
DRMA income_statement (quarterly, 2025-03-31) — Salaries And Wages: 339018.00
DRMA income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 0.00
DRMA income_statement (quarterly, 2025-03-31) — Selling General And Administration: 1058662.00
DRMA balance_sheet (quarterly, 2025-03-31) — Share Issued: 603264.00
DRMA cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 37189.00
DRMA balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 7301222.00
DRMA balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 7301222.00
DRMA income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
DRMA income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
DRMA balance_sheet (quarterly, 2025-03-31) — Total Assets: 10005007.00